Non-Drowsy Sudaplus (Pseudoephedrine Hydrochloride, Paracetamol)

Pseudoephedrine Hydrochloride and Paracetamol, the active ingredients in Non-Drowsy Sudaplus, are a decongestant and an analgesic/antipyretic presented as an oral tablet for oral use. They relieve nasal congestion, headache, fever, and pain associated with the common cold in adults and children.

GNH USA supplies Non-Drowsy Sudaplus as a licensed, GDP‑compliant international pharmaceutical supplier serving pharmacies and clinics worldwide.

Non-Drowsy Sudaplus combines a nasal decongestant and an analgesic/antipyretic to address symptoms of upper respiratory infections.

- Nasal congestion: reduces swelling of nasal mucosa to improve airflow. - Headache: alleviates pain associated with cold‑related tension. - Fever: lowers elevated body temperature. - Pain associated with cold: provides relief from sore throat and muscle aches.

Common Side Effects: - Insomnia: difficulty falling or staying asleep. - Nervousness: feeling of restlessness or jitteriness. - Dry mouth: reduced salivation. - Nausea: mild stomach upset. - Dizziness: light‑headed sensation.

Serious or Rare Side Effects: - Hypertension: significant increase in blood pressure. - Cardiac arrhythmia: irregular heart rhythm. - Severe allergic reaction: rash, swelling, or breathing difficulty. - Liver injury: elevated liver enzymes or jaundice. - Seizures: rare neurologic events.

Before using Non-Drowsy Sudaplus, consider the following safety measures.

- Assess cardiovascular status: patients with hypertension or heart disease should be evaluated. - Review concomitant medications: avoid duplicate decongestants or paracetamol. - Monitor renal function: caution in patients with kidney impairment. - Avoid use in children under the recommended age without medical advice. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Non-Drowsy Sudaplus may interact with several drug classes; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Other sympathomimetic agents: additive vasoconstrictive effects. - Additional paracetamol‑containing products: risk of hepatotoxicity. - Certain antidepressants (e.g., tricyclics): increased cardiovascular strain.

Moderate Interactions (Monitor Closely):\n- Antihypertensive drugs: possible reduction in blood‑pressure‑lowering effect. - Anticoagulants (e.g., warfarin): potential alteration of INR. - Antidiabetic agents: may affect glucose control. - Alcohol: enhances liver stress and sedation risk.